18F－PSVue643 PET/近红外肿瘤凋亡显像  

In vivo detection of tumor apoptosis using a novel PET/NIRF imaging probe： 18F-PSVue643

作　　者：王欣璐[1] 李国权[2] 张金赫[1] 李向东[1] 周崝[1] 欧阳习[1] 尹吉林[1] 

机构地区：[1]广州军区广州总医院核医学科PET/CT中心,510010 [2]第四军医大学西京医院核医学科,西安710032

出　　处：《中华核医学与分子影像杂志》2016年第6期529-532,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金（81571733）;教育部第49批留学回国人员科研启动基金;广州市科技专项产学研重点项目（201504291018521）;广东省科技计划面上项目（2014A020212261）

摘　　要：目的 用新型NIRF和正电子分子探针18F－PSVue643评估细胞凋亡，比较2种方法的优缺点。方法 用MTT法和流式细胞术评估紫杉醇体外诱导肿瘤细胞凋亡的情况。建立U87MG胶质母细胞瘤荷瘤裸鼠模型，采用视黄醇和紫杉醇联合静脉注射进行全身化疗，诱导体内肿瘤细胞凋亡，分别于化疗后第9天和第11天用18F－PSVue643进行小动物PET显像和NIRF成像，根据图像勾画ROI，计算靶组织放射性摄取值（%ID/g），并根据图像进行2种显像方法的对比研究。结果 体外细胞学实验及静脉注射治疗均证实紫杉醇可诱导肿瘤细胞凋亡。10、100 nmol/L紫杉醇处理组凋亡细胞的占比分别为7.4%和7.5%，高于对照组的4.3%。NIRF成像和PET显像均显示，18F－PSVue643可特异性与凋亡细胞结合，达到凋亡显像的目的。仅需光学成像一半的探针用量，PET显像即可获得相同的凋亡成像效果。 结论 18F－PSVue643可同期进行凋亡NIRF成像和PET显像，是一种有发展前景的肿瘤凋亡显像剂。Objective To evaluate the ability of a synthetic PET/NIRF probe, named 18F-PSVue643, on the apoptosis detection in animal models with the anti-cancer drugs therapy, and compare the advantages and disadvantages between PET and NIRF.Methods Cell apoptosis was detected by MTT and flow cytometry in vitro. Established U87MG glioblastoma xenograft tumors in nude mice were treated with retinol and paclitaxel for nine days （for PET imaging） or eleven days （for NIRF imaging） continuously. The uptake values were recorded by ROI and expressed as %ID/g.Results The apoptosis ratios in 10 and 100 nmol/L paclitaxel-treated groups were 7.4% and 7.5%, respectively, and the apoptosis ratio of the control group was 4.3%. The apoptosis could be well detected by both NIRF and PET imaging during the whole process of treatment. However, the amount of probe for PET imaging was only a half of that for optical imaging to get the same apoptosis visualization.Conclusion 18F-PSVue643 is suitable for NIRF and PET imaging in detection of apoptosis, and it may be a promising agent for further clinical studies.

关 键 词：分子探针 磷脂酰丝氨酸类 胶质母细胞瘤 细胞凋亡 体层摄影术 发射型计算机 光学成像 小鼠 裸 

分 类 号：R730.44[医药卫生—肿瘤]